Compare UNTY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | ZVRA |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 562.2M |
| IPO Year | 2014 | 2015 |
| Metric | UNTY | ZVRA |
|---|---|---|
| Price | $59.25 | $12.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.00 | $23.00 |
| AVG Volume (30 Days) | 39.7K | ★ 775.2K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 39.66 | ★ 159.21 |
| EPS | ★ 2.82 | 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $12.14 | $37.27 |
| Revenue Next Year | $9.56 | $53.42 |
| P/E Ratio | $21.26 | ★ $16.76 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $44.34 | $7.16 |
| 52 Week High | $62.50 | $15.04 |
| Indicator | UNTY | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 62.83 |
| Support Level | $51.27 | $12.18 |
| Resistance Level | $60.49 | $14.27 |
| Average True Range (ATR) | 1.22 | 0.41 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 53.31 | 86.09 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.